Loading company…
Swedish Orphan Biovitrum AB (Sobi) is a Stockholm biopharmaceutical company formed in 2010 through a merger with Biovitrum.
Based in Stockholm, Sweden, Swedish Orphan Biovitrum AB (Sobi) was formed in 2010 through the merger of Swedish Orphan International and Biovitrum. The company develops and supplies drugs for haematology, immunology, and genetic and metabolic diseases, including extended half-life factor replacement treatments for haemophilia A and B. In November 2006, Biovitrum raised SEK 770 million in an IPO, selling 7.7 million shares at SEK 100 each on Nasdaq Stockholm. It is at the Seed stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in